Checking out PE 22-28 for mood support – what do you think?

Question

I’ve been looking at the PE 22-28 page on the site it’s a spadin‑derived TREK‑1 blocker that’s being studied as a fast‑acting antidepressant in animal models. The mechanism makes sense to me – blocking that potassium channel should boost serotonergic signaling and could explain the rapid synaptogenesis they see in mice. I’ve tried a few nootropic peptides before and usually track mood with a simple daily rating scale, so I’m curious if anyone has seen any human anecdotal reports or small pilot trials on this one. The preclinical data looks promising, but the lack of human safety info makes me cautious about jumping in without more data.

brandon245 · Accepted Answer

Not gonna lie, I haven’t tried PE 22‑28 yet. I’ve used a couple of peptides like BPC‑157 for post‑workout injuries and a bit of oxandrolone for muscle recovery, but no one has pushed me into the mood‑space yet. Your take on the TREK‑1 block is solid, blocking a potassium channel can give serotonin a lift, and the synaptogenesis seen in mice is intriguing. I’d be cautious until someone posts a human safety profile or a small pilot. If you hear anything about dosing or early trials, let me know. How do you think about balancing the fast‑acting promise with the need for more data?

amber464 · Answer

Thanksürzt. I’m in the same boat – no human data, so I’m holding off on dosing until I see any safety reports or pilot results. I’ll keep an eye on the biotech forums and any pre‑entry human studies that pop up. Do you think a conservative 7‑10 µg dose what some users suggest for related peptides would be a sensible starting point if we did get a trial?

aspiring_codes · Answer

Agree entirely on needing human data before jumping in, preclinical is one thing, real people another. I’ve been curious about PE 22-28 but stuck waiting for any small pilot trials or even just someone’s “for me” experience. Wonder if you’ve looked into any other fast-acting options while waiting? 👀

amber464 · Answer

Thanks for Fedora. I’ve been keeping an eye on ketamine sub‑lingual and a few low‑dose psilocybin protocols – both have small human safety data, but the dosing and tracking are a bit more arcane. I’ve been logging mood on a 1–10 scale and HRV nightly to see if any spike appears. Which fast‑acting agents are you tracking while you wait for trials?

Checking out PE 22-28 for mood support – what do you think?

Comments